

CIGNA CORP
Form 425
June 01, 2018

Filed by Cigna Corporation
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934

Subject Company: Cigna Corporation and Express Scripts Holding Company
(Commission File No. 001-08323)
Date: June 1, 2018

The following is a transcript of a video that Cigna Corporation added to the deal website,
www.advancinghealthcare.com.

Insights from Fiona Scott Morton

Fiona Scott Morton is the former Chief Economist at the Department of Justice and the Theodore Nierenberg Professor of Economics at the Yale School of Management.

(Fiona Scott Morton)

We are spending almost eighteen percent of GDP on health care and that's just projected to rise, so I think that the social pressure and the political pressure on the health care economy is really large right now to try to think of some creative solutions that will bring down health care costs.

Why bring together insurers and PBMs?

You've seen a couple of combinations of insurers and PBMs already. It makes sense because the drugs that you take affect your health and the health that you have affects the drugs that you need. It's rather a circular system. I think that's pretty obvious and intuitive to most people, but the kind of actual data to show how important that is, and how much it matters to put health and pharma into the same organization, has really showed up fairly recently in the economics literature.

And what these papers in the literature show is that the combined entity actual does do a lot better job reducing out-of-pocket costs for consumers for drugs that lower overall expenditures. That corporation then has as a bottom line, the total health expenses of the consumer...and that would be their pharma expenses, their medical expenses, maybe their mental health expenses. They have an incentive to coordinate those things to keep the consumer as healthy as possible so the expenses are low. So that's a really good sign that these transactions are heading in a good direction for overall health care costs.

What factors make Cigna & Express Scripts a compelling match?

Cigna's strategy is really the strategy of innovation, wellness, coordinated care. If you're trying to do that without the best possible PBM, the best possible pharmaceutical input, it's going to be harder. You know, Express Scripts is a very large and very capable PBM with a lot of experience and knowledge of this sector and so put the capabilities of Express Scripts together with the capabilities of Cigna, gives the combined firm a chance to really do that whole wellness, innovation, keep you out of the hospital thing, with the full panoply of the pharma piece fitting in there, and I think there's a possibility of really good consumer benefits from that.

What can Cigna and Express Scripts expect from a regulatory perspective?

When you come out with a transaction like this and ask, "How might this affect the competitive landscape? How might this affect competition and consumers?", it might be that somewhere in the vertical merger there's an implication for horizontal competition and a problem created for horizontal competition.

I think the example everyone is thinking about these days is AT&T-Time Warner, where the idea there is that AT&T will obtain through the Time Warner acquisition valuable content like HBO, and that HBO content would normally be sold to Comcast, Dish and other outlets that are direct horizontal competitors of AT&T...so AT&T might want to – I mean, what the government's theory is explaining is that AT&T might want to raise the price of HBO to Dish – and that would make Dish more expensive and cause Dish's customers to want to buy DirecTV, which belongs to AT&T. We

don't really have that same problem in this merger because Express Scripts is selling PBM services, but they're not must-have PBM services. I mean, if you don't have HBO, you don't have Game of Thrones, and there's other things you can watch on TV, but there isn't really an exact substitute for Game of Thrones. Whereas when you're talking about PBM services – that's pills being delivered in mail order and a formulary – there are actually multiple competitors that supply that service. It's a much different landscape in terms of the intensity of the foreclosure problem.

When the Department of Justice looks at transactions like this, they're really trying to look at two pieces: any potential anticompetitive effects and then the efficiencies...what's going to be better...what's going to be lower cost or better quality. And I think we see in the academic literature that the efficiencies here are really substantial. If that turns out to be true, then these are going to be transactions that are easy to approve because with a large efficiency that's a kind of merger that you want, and that's going to lower health care costs.

FORWARD LOOKING STATEMENTS

Information included or incorporated by reference in this communication, and information which may be contained in other filings with the Securities and Exchange Commission (the "SEC") and press releases or other public statements, contains or may contain forward-looking statements. These forward-looking statements include, among other things, statements of plans, objectives, expectations (financial or otherwise) or intentions.

Forward-looking statements, including as they relate to Express Scripts ("Express Scripts") or Cigna ("Cigna"), the management of either such company or the transaction, involve risks and uncertainties. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Express Scripts and Cigna do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the risks associated with the following:

- the inability of Express Scripts and Cigna to obtain stockholder or regulatory approvals required for the merger or the requirement to accept conditions that could reduce the anticipated benefits of the merger as a condition to obtaining regulatory approvals;
- the possibility that the anticipated benefits from the merger cannot be realized in full, or at all or may take longer to realize than expected;
- a longer time than anticipated to consummate the proposed merger;
- problems regarding the successful integration of the businesses of Express Scripts and Cigna;
- unexpected costs regarding the proposed merger;
- diversion of management's attention from ongoing business operations and opportunities;
- potential litigation associated with the proposed merger;
- the ability to retain key personnel;
- the availability of financing;
- effects on the businesses as a result of uncertainty surrounding the proposed merger; and
- the industry may be subject to future risks that are described in SEC reports filed by Express Scripts and Cigna.

You should carefully consider these and other relevant factors, including those risk factors in this communication and other risks and uncertainties that affect the businesses of Express Scripts and Cigna described in their respective filings with the SEC, when reviewing any forward-looking statement. These factors are noted for investors as permitted under the Private Securities Litigation Reform Act of 1995. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider either foregoing lists, or the risks identified in SEC filings, to be a complete discussion of all potential risks or uncertainties.

IMPORTANT INFORMATION ABOUT THE TRANSACTION AND WHERE TO FIND IT

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. In connection with the proposed transaction, on May 16, 2018, the newly formed company which will become the holding company following the transaction (“Holdco”) filed with the SEC a preliminary registration statement on Form S-4 that includes a joint proxy statement of Cigna and Express Scripts that also constitutes a prospectus of Holdco. These materials are not final and may be amended. Cigna and Express Scripts also plan to file other relevant documents with the SEC regarding the proposed transaction. This document is not a substitute for the registration statement or the joint proxy statement/prospectus or any other document which Cigna, Express Scripts or Holdco may file with the SEC.

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY REGISTRATION STATEMENT, JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. You may obtain a free copy of the preliminary registration statement on Form S-4 filed on May 16, 2018 and the definitive joint proxy statement/prospectus (if and when it becomes available) and other relevant documents filed by Holdco, Cigna and Express Scripts with the SEC at the SEC’s website at www.sec.gov. Copies of documents filed with the SEC by Cigna will be available free of charge on Cigna’s website at www.Cigna.com or by contacting Cigna’s Investor Relations Department at (215) 761-4198. Copies of documents filed with the SEC by Express Scripts will be available free of charge on Express Scripts’ website at www.express-scripts.com or by contacting Express Scripts’ Investor Relations Department at (314) 810-3115.

PARTICIPANTS IN THE SOLICITATION

Cigna (and, in some instances, Holdco) and Express Scripts and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction under the rules of the SEC. Investors may obtain information regarding the names, affiliations and interests of directors and executive officers of Cigna (and, in some instances, Holdco) in Cigna’s Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on February 28, 2018, and its definitive proxy statement for its 2018 Annual Meeting, which was filed with the SEC on March 16, 2018. Investors may obtain information regarding the names, affiliations and interests of Express Scripts’ directors and executive officers in Express Scripts’ Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on February 27, 2018, and its proxy statement for its 2018 Annual Meeting, which was filed with the SEC on March 29, 2018. You may obtain free copies of these documents at the SEC’s website at www.sec.gov, at Cigna’s website at www.Cigna.com or by contacting Cigna’s Investor Relations Department at (215) 761-4198. Copies of documents filed with the SEC by Express Scripts will be available free of charge on Express Scripts’ website at www.express-scripts.com or by contacting Express Scripts’ Investor Relations Department at (314) 810-3115. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction if and when they become available. Investors should read the joint proxy statement/prospectus carefully and in its entirety when it becomes available before making any voting or investment decisions.

NO OFFER OR SOLICITATION

This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.